

Corporate Overview

July 2022

Nasdaq: BIOC

www.biocept.com



Forward-Looking Statements

This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding Biocept, Inc. and our business. Forward-looking statements include all statements that are not historical facts and generally can be identified by terms such as anticipates, believes, could, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would, or the negative of those terms and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For details about these risks, please see our SEC filings.

All forward-looking statements contained in this presentation speak only as of the date hereof, and except as required by law, we assume no obligation to update these forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Investment Highlights

- Pioneering proprietary CNSide™ assay using cerebrospinal fluid (CSF) to test for cancer involvement in the central nervous system (CNS); initial U.S. market opportunity of \$1.2B
- Expanding CNSide usage among neuro-oncologist KOLs; 23 of 64 NCI-Designated Cancer Centers using CNSide
- Pursuing CNSide standard of care status to support broader adoption and higher reimbursement by generating clinical data through FORESEE and company-sponsored investigator studies
- Targeting collaborations with biopharma partners using CNSide assay to support therapeutics clinical trials
- Serving the community and supporting our cash position with COVID-19 RT-PCR testing

Dedicated to improving outcomes for patients with advanced cancer.




A blurred background image of a hospital hallway with people walking and overhead lights.

Neuro-Oncology

Market Overview

Recent Trends in U.S. Deaths Due to Cancer

- Cancer deaths in aggregate declined >25% from 2000 to 2019 due to improved screening, diagnosis and prevention, lower smoking rates, and improved treatments
- Deaths due to cancer of the brain and other nervous system (ONS) have unfortunately remained stable
- Metastasis accounts for 90% of all solid tumor cancer mortality¹




1. Taftaf, R. et al. Nature Communications 12, 4867 (2021).

Leptomeningeal Metastases (LM)

- Cancer cells in the subarachnoid space/CSF
- Solid and Hematologic malignancies
- Symptoms:
 - High intracranial pressure and/or spinal cord compression
 - Cranial nerve symptoms
 - Spinal cord and nerve root involvement causing extremity weakness, paresthesia and/or pain.

Frequency of LM by Solid Tumor Type ¹⁻⁴	
Breast cancer	12-35%
Lung cancer	10-26%
Melanoma	5 - 25%
Gastrointestinal	4 - 14%
Unknown Primary	1-7%



LM Overall Solid Tumor Incidence

3-8% of solid tumor patients will be diagnosed with LM during the course of their illness¹⁻³

20% of cancer patients demonstrated LM at autopsy⁴⁻⁸


40% of patients positive at autopsy had negative CSF cytology prior to death^{4,5}

On average, leptomeningeal metastasis is detected **3.5X** more frequently at autopsy than it is diagnosed clinically

LM Unmet Clinical Needs

➤ Underdiagnosed⁵⁻⁸


- MRI: low positive predictive value
- Cytology: low overall sensitivity



MRI Imaging⁵

Sensitivity
75%

Specificity
77%



CSF Cytology^{6,7,8}


Sensitivity
50%

Specificity
95%


➤ Undertreated^{1,2,3,4,9}

- Average survival w/o therapy: 4-6 weeks
- Average survival w/ therapy: 2-4 months
- Average survival w/ targeted therapy: 11-19 months

Breast⁹



NSCLC³



1. Batool A. Leptomeningeal Carcinomatosis. StatPearls; 2022.
2. J Neurooncol. 2013 Sep;114(2):229-35.
3. J Thorac Oncol. 2012 Feb;7(2):382-5.
4. Ann Oncol. 2020 Oct;31(10):1397-1404.

5. Int J Cancer. 2015 Jan 1;136(1):162-71.
6. Arq Neuropsiquiatr. 2013 Sep;71(9B):677-80.
7. Semin Oncol. 2009 Aug;36(4 Suppl 2):535-45.
8. Neurology. 1979 Oct;29(10):1369-75.
9. Breast Cancer Res Treat. 2019 Jun;175(3):781-788.

2022 Independent Market Research – U.S.

CNSide TAM (# of patients/year)	Literature Sources	Market Research
Diagnosis TAM parenchymal brain metastases (rule out LM)	112,000	101,800
Treatment/Monitoring TAM parenchymal brain metastases	59,400	54,000
Diagnosis TAM LM	41,100	56,700
Treatment/Monitoring TAM LM	21,800	30,100
TOTAL	234,300	242,600

For LM:
**Diagnosis and
Therapy Selection**

**Total Segment:
\$160M**

For PBM:
**Diagnosis and
Therapy Selection**

**Total Segment:
\$287M**

For LM:
**Therapy Response,
Disease Monitoring**

**Total Segment:
\$255M**

For PBM:
**Therapy Response,
Disease Monitoring**

**Total Segment:
\$457M**

**Aggregate TAM for Diagnosis, Profiling,
and Monitoring in LM and PBM:**

**Total Market:
\$1.2B**

CNSide

Assay Technology, Attributes, and Data



First commercially available real time method to measure biomarker status of CNS

- Intended to determine the presence, quantity, and characterization of malignant cells in CSF
- Currently performed primarily for suspicion of or diagnosis for LM

CLIA-Validated Test for **Metastatic Carcinomas***



- ✓ Sensitivity: 92%
- ✓ Specificity: 100%

*(N=79 Clinical CSF Samples¹)



CNSide Identifies Biomarkers & Drug Targets in CSF

- Tumor cells circulating in blood (CTCs) can infiltrate the CSF (a cul-de-sac) forming the basis for CNS metastasis
- ctDNA and ctRNA derived from tumors can be shed into blood or CSF as cells die, but **they do not confirm metastasis**
- Biocept analyzes tumor cells and cell-free DNA in CSF for diagnosis, biomarker status, and monitoring




CNSide Addresses Several Unmet Clinical Needs

Detection of LM can be improved using cell capture technology


Therapeutic **target selection** can be informed by multiplexing cellular and molecular assays on single samples

Quantifying results for longitudinal observations allows for disease **monitoring**


Is there **TUMOR**




Is there **TARGET**



Is there **TREND**



Biocept CNSide Proprietary Technology and Workflow*



Biocept IP Portfolio – 42 Patents Issued Worldwide

Family 1 MicroChannel for CTC Capture <ul style="list-style-type: none"> ▶ Recovery of Rare Cells using Microchannel ▶ Device for Cell Separation & Analysis 	Issued in US (3), China (3), EU PTO, Hong Kong (3), Japan, S. Korea, Canada	Expire 2025-2027
Family 2 CTC Capture With Antibody Cocktail <ul style="list-style-type: none"> ▶ Subfamily 1 – Devices & Methods of Cell Capture Analysis ▶ Subfamily 2 – Method and Reagents for Signal Amplification 	Sub 1) Issued in US (3), Australia (2), Canada, China, EU PTO (2), Hong Kong, Japan (4) Sub 2) Issued in US, Canada, China, EU PTO, Hong Kong, Japan	Expire 2030-2031
Family 3 Collection Tube <ul style="list-style-type: none"> ▶ Use of DU for Anti-Clumping of Biological Sample 	1) Issued in US	Expire 2031
Family 4 – <i>In licensed from Aegea</i> Switch-Blockers for use in real time PCR on CSF samples <ul style="list-style-type: none"> ▶ Methods for Detecting Nucleic Acid Sequence Variants 	1) Issued in US, Australia, EU PTO, Brazil, China, Hong Kong, Japan, S. Korea	Expire 2032

CNSide Publications, Posters, and Abstracts

Eight Published CNSide Documents to Date

Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) from CSF

Katker V, Gori, Viree Singh, Shrikant, David Lussman, Marlene Vossler, Alexander J. Javani, David J. Rothman, Katherine A. Goh, Melissa A. Accardo

Target Selector™: cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvement

Viree M. Singh, MD, Deanna M. Fisher, PhD, Robbin D. Schultz, PhD, Julie A. Mayer, PhD, Smitha Borgula, Jaya Gopi, Mithun Nigam, Judy Truong, Lucia Dolan, Jose Aguilar, Carlos, Karen Kopp, MD, and Sarath Kesan, MD, PhD

Beyond Cytology – A Single Institution Experience Using CNSide™ for Diagnosing and Monitoring Treatment Response in Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis (LMC)

Walid Aklefi, Samir Patel, Anna Chamer, Kathleen Berger, Sherry Patel, Barbara Blouw, Smitha Borgula, Robbin D. Schultz, Joanna Liberi, Anna Natsopoulos, Michael Daguerre, and Julie Mayer

Case Series of Multi-Institutional Utility of CNSide™ to Manage Leptomeningeal Disease in Patients with Metastatic Breast Cancer

Michael Dugan (MD), Deanna Fisher (BS), Nathan Sweed (MD), Barbara Blouw (PhD), Anna Natsopoulos (BS), Smitha Borgula (MS), Robbin D. Schultz (PhD) and Julie Mayer (PhD)

CSF to Capture Demonstrates Improved Tumor Cell Capture Rate Compared to Cytology

Nancy A. Bousquet, PhD, David J. Rothman, PhD, and Julie Mayer, PhD

Characterization of HER2 Amplification in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease in Stage IV Patients with Breast Cancer

Michael Dugan (MD), Deanna Fisher (BS), Nathan Sweed (MD), Barbara Blouw (PhD), Anna Natsopoulos (BS), Smitha Borgula (MS), Robbin D. Schultz (PhD) and Julie Mayer (PhD)

Polymy of Chromosome 17 in patients with equivocal HER2 FISH results on the primary tumor

Christine A. Goh, PhD, David J. Rothman, PhD, and Julie Mayer, PhD

Composition biomarkers in primary tumor vs CSF

Christine A. Goh, PhD, David J. Rothman, PhD, and Julie Mayer, PhD

AAN April 2022: Longitudinal Use in Multiple Tumor Types & Longitudinal Genetic Heterogeneity of HER2 Status

Saint John's
Health Center
Providence

PACIFIC
NEUROSCIENCE
INSTITUTE®

Using Cerebrospinal Fluid Tumor Cell (CSF-TC) Assays to Track Disease Burden and Treatment Response in Patients with Leptomeningeal Metastasis

Akanksha Sharma,¹ Nathan Sneed,² Barbara Blouw,² Deanna Fisher,² Kaitlyn Armiijo,² Steven Hsiao,² Anna Natasha,² Shiyi Hua,² Pericles Corkos,² Tony Pircher,² Naveed Wagle,¹ Jose Carrillo,¹ Minh Nguyen,¹ Judy Truong,¹ Michael Dugan,² Santosh Kesari¹

¹Department of Translational Neurosciences,
Pacific Neuroscience Institute/Providence Saint John's Cancer Institute,
²Biocept, Inc.

Background

- Leptomeningeal metastasis (LM) is diagnosed in approximately 5% of patients with metastatic cancer and has a dismal prognosis (4-6 weeks, untreated)
- Imaging, clinical exam, and cytology all have limited capability for diagnosis and disease monitoring of LM

Methods

- Five (5) cases of LM were diagnosed and followed using the Biocept™ CNSide™ platform
- For each specimen, approximately 6-8 mL of CSF was obtained and transported using the CNSide assay's proprietary tubes
- Each specimen underwent CSF-TC capture, immunocytochemistry (ICC), and (when applicable) fluorescence in situ hybridization (FISH)

Patient Demographics

Patient	Sex	Age	Primary	Treatment	OS
1	F	40	Breast (HER2+)	Tucatinib, IT Methotrexate, IT Cytarabine, IT Trastuzumab (Added), IT Pemetrexed (Added)	17 mos
2	M	70	Melanoma (PD-L1+)	IT Cytarabine, IT Thiotepa	10 mos
3	M	63	Esophageal (HER2+)	IT Topotecan, IT Trastuzumab (Added)	2 mos
4	F	59	Breast (ER+, PR+)	IT Cytarabine, IT Methotrexate	7 mos
5	M	76	Neuroendocrine Carcinoma	Capecitabine, Temozolomide	5 mos

OS - Overall Survival, IT - Intrathecal

Learn more about the CNSide assay



Conclusions The CNSide assay shows significant advantages in monitoring treatment response and disease course in LM

- The CNSide assay identifies biomarkers in LM patients for which targeted therapeutic interventions can significantly improve neurological symptoms and survival
- Additional longitudinal trials to assess the utility of this platform for LM patients are warranted


Biocept
Completing the Answer™

CSF-TC Capture Demonstrates Improved Tumor Cell Capture Rate Compared To Cytology


CSF tumor cell capture and HER2 amplification on CSF Tumor cells					
Collection Date	Cytology Result	CNSide Result	CNSide Count	HER2 Result	HER2 Count
7/22/2020	Positive	Positive	3123.00	Detected	2.17
8/11/2020	Positive	Positive	1621.47	Detected	0.64
8/25/2020	Positive - rare	Positive	25.81	Detected	17.91
9/1/2020	Positive - rare	Positive	1.45	Not Detected	0
9/8/2020	Negative	Positive	1.40	Not Detected	0
9/15/2020	Positive	Positive	0.20	Not Detected	0
9/29/2020	Negative	Positive	1.08	Not Detected	0
10/10/2020	Negative	Positive	3.00	Not Detected	0
10/20/2020	Negative	Positive	1.17	Not Detected	0
10/27/2020	Negative	Positive	1.25	Not Detected	0
11/9/2020	Negative	Positive	0.61	Not Detected	0
11/17/2020	Negative	Negative*	0.17	NA	0
12/1/2020	Negative	Positive	1.43	Not Detected	0
1/12/2021	Positive	Positive	204.54	Detected	2.00
1/18/2021	Positive	Positive	207.63	Detected	6.00
1/27/2021	Positive	Positive	17.00	Detected	2.74
2/3/2021	Negative	Positive	0.50	Not Detected	0
2/4/2021	Negative	Negative	0.00	NA	0
2/14/2021	Negative	Positive	0.20	Not Detected	0
2/23/2021	Negative	Negative	0.00	NA	0
3/2/2021	Negative	Negative	0.00	NA	0
3/23/2021	Negative	Positive	0.33	Not Detected	0
4/1/2021	Positive	Positive	14411.00	Not Detected	0
4/15/2021	Positive	Positive	502.00	Detected	25.00
4/22/2021	Positive	Positive	2494.71	Not Detected	0
4/29/2021	Positive	Positive	558.57	Not Detected	0
7/6/2021	Positive	Positive	439.23	Not Detected	0
7/13/2021	Positive	Positive	554.63	Detected	1.00
7/20/2021	Positive	Positive	144.67	Not Detected	0
7/27/2021	Positive	Positive	527.00	Detected	4.00
8/3/2021	Positive	Positive	241.17	Not Detected	0
8/10/2021	Positive	Positive	256.33	Not Detected	0
8/17/2021	Positive	Positive	535.67	Not Detected	0
9/30/2021	N/A	Positive	1726.00	Detected	1.00
10/14/2021	N/A	Positive	8064.00	Not Detected	0
10/28/2021	N/A	Positive	748.00	Detected	3.00
11/4/2021	N/A	Positive	257.25	Not Detected	0
11/18/2021	N/A	Positive	221.56	Not Detected	0

*Test Result did not Exceed Normal Cutoff Value (1 CK+ Cell and/or 2 CK- Cells)

- Patient 1 - Breast cancer HER2+**
- CNSide assay HER2 FISH results informed the addition of IT Trastuzumab
 - Patient moved overseas in August 2021, expired in late 2021
- Patient 2 - Melanoma with multiple intracranial recurrences**
- LM was well controlled throughout treatment course
 - Patient went on hospice after parenchymal mass invaded optic chiasm, causing blindness
- Patient 3 - Esophageal cancer**
- CNSide assay HER2 FISH results informed the addition of IT Trastuzumab
 - Patient transferred providers, no treatment information following 9/7/21
- Patient 4 - Breast cancer ER/PR+**
- Diagnostic LP (8/4/21) - CNSide assay detected 1284 tumor cells; cytology was positive, but a differential count by pathologist found only 72 tumor cells
 - Patient responded well to IT chemo and her LM remained under control but she progressed with systemic disease and expired
- Patient 5 - Large cell neuroendocrine carcinoma**
- Diagnostic LP (8/4/21) - Cytology negative; the CNSide assay detected 194 tumor cells
 - Cytology consistently negative in this patient
 - Functional status declined and patient transitioned to hospice




CSF-TCs Track Disease Status and Therapy Response



Case Study Demonstrating CNSide™ Utility¹


40-year-old Female

- Breast Cancer Primary Tumor
- Diagnosed with LM






CSF tumor cell numbers detected by the CNSide assay correlated with treatment status

- ▶ 38 unique CSF specimens (Median = 7, SD = 3.36 mL)
- ▶ CSF-TC counts are normalized by volume
- ▶ LM directed treatment and cessation correlated with CSF tumor cell number



Promising Early Commercial Adoption of CNSide





FORESEE Clinical Trial

A Prospective, Multi-Institution Study Led by Northwestern University

Biocept's Clinical Trial - FORESEE Study (NCT#: NCT05414123)


Objectives:

- To determine the impact of CNSide in managing Leptomeningeal Metastasis in patients with Breast or Non-Small Cell Lung Cancer
- Assess correlation of CSF Tumor cells with clinical response
- Evaluate CNSide in helping to determine course of treatment
- Study design:



FORESEE Trial Schema

- CNSide, imaging, CSF cytology and clinical results collected at baseline and 3 consecutive time points
- Tumor cell detection by CNSide will be correlated with response to treatment
- Impact of CNSide on treatment decision making will be assessed via physician questionnaire



A blurred background image of a hospital hallway with people walking and overhead lights.

The Opportunity

Building shareholder value with CNSide

CNSide Commercial Strategy

- 1 **Expand CNSide Usage Among Thought-Leaders**
 - Generate further engagement, experience, and advocacy for CNSide with this small core of experts and leaders
- 2 **Develop the Market**
 - Expand adoption through publication of FORESEE and company-sponsored investigator clinical utility results, KOL presentations, and exceptional customer experience
 - Expand to additional neurological indications
- 3 **Gain high-value reimbursement of >\$4,000 per assay**
 - Near-term expansion of high-value biomarker coverage
 - Transition to global coding and payment at proprietary pricing as clinical utility evidence develops
- 4 **Inclusion in NCCN Guidelines for LM**
 - Support repeat testing for therapy response monitoring
 - Expand adoption to medical oncologists

Target Market


- ▶ Neuro-oncologists and thought leaders for early adoption (<1,000)
- ▶ Medical Oncologists (>12,000)

Commercial Focus on Product Development, Expanded Clinical Use, and Price Enhancement

2022 Quantitative Market Research

Key Survey Findings from 150 Medical Oncologists

A majority are highly likely to use CNSide for diagnosis and therapy choice and more than half are highly likely to use CNSide for monitoring LM and parenchymal brain metastases



Biocept in the CSF Liquid Biopsy Market

1 Leptomeningeal Metastasis

Establish CSF beachhead in area with critical unmet needs

- Significantly advance patient care and management
- >200,000 with CNS involvement¹

2 PBM & Gliomas

Expand to other neuro-oncology indications

- Parenchymal brain metastases
- Primary brain tumors

3 Brain Metastases Screening


Enable earlier detection

- Emerging evidence of which high-risk primary solid tumors are associated with metastases
- Establish clinical evidence of utility

4 Other neurological diseases

CSF analysis as a window into other CNS disease processes²

- Especially where cellular process are involved
- Potential for neurodegenerative disease




1. <https://www.cancernetwork.com/view/management-brain-metastases>
<https://www.cancer.gov/about-cancer/understanding/statistics>

2. Busse et al, *Brain Behav Immun Health*; V.14;2021 Jul

CNSide Biopharma Services – The Market Opportunity for CNS Metastases


CNS Metastases Studies Initiated from 2003-2022*



* Information obtained from <http://www.clinicaltrials.gov>

Key Catalysts for Growth

- Incidence of brain metastases is rising as result of increased survival and improved prognosis (~30% of patients) → Data from autopsy cohorts suggest incidence much higher¹
- Biopharma is investing heavily in CNS metastases therapeutic development – **100 programs initiated in past 5 years**
- LM-focused studies have more than tripled in the past 15 years
- Advancements in local and systemic therapies have improved median survival following initial CNS metastasis treatment^{2,3}
- Cancer Moonshot Initiative & ASCO recommendations⁴: FDA is working with sponsors to improve eligibility criteria of CNS metastases
 - Urges metastatic patient inclusion in early-phase studies
 - Recommends inclusion of LM in early-phase trials of drugs with anticipated CNS activity
- Most CNS metastasis studies are in early phases → gives Biocept the opportunity to incorporate CNSide in protocol
- Parenchymal CNS metastases comprise the largest segment – Biocept IST trials will establish performance of CNSide in these populations and document new intended uses



Opportunity	Stage
World Leading Cancer Inst. Breast Research Group	New Prospect!!
Top Tier Biopharma	New Prospect!!
Top Tier Biopharma	New Prospect!!
Major Cancer Research Network BC-IPBM Study	SOW submitted
Emerging Biopharma cMet Glioma Study	SOW Submitted
Emerging Biopharma NTRK LC-IPBM Study	Proposal Stage
Plus Therapeutics 186RNL LM Study	Contract Closed 1 st Patient Enrolled

Leveraging Expertise to Provide COVID-19 RT-PCR Testing

- **>920,000+ COVID-19 samples received for SARS-CoV-2 testing since launch in June 2020**
- Diverse base of business in clinics, skilled nursing and colleges leads to repeat testing per client
- Fast turnaround times with vast majority of results reported in <48 hours
- Performed with RT-PCR EUA molecular diagnostic platform
- Testing performed in high-complexity, CLIA-certified and BSL-2 safety level lab by licensed molecular lab staff trained to perform COVID-19 testing

Agreement with California Community Colleges

- Providing access to testing as students return to in-person classes
- Collaboration to provide a system for tracking and managing COVID-19 testing requirements and test results

COVID-19 Volume Drives Revenue Growth, Reducing Cash Burn


Medicare Reimbursement

- \$100 per test

Lab Capacity to Meet Demand

- COVID-19 volume drove increased capacity
- Automation and investment in additional molecular technologies to meet demand
- Ability to ramp to >10,000 tests per day

Supports Investment in Core Neuro-Oncology Business



A blurred photograph of a modern hospital hallway with white walls, glass doors, and recessed ceiling lights. The perspective is looking down the length of the corridor.

The Team

Leadership Team

Sam Riccitelli
Chair, Interim President & CEO

- Seasoned executive with 35+ years medical device & diagnostics experience
- Serial oncology diagnostics entrepreneur
- Former COO at Genoptix, Inc.

Antonino Morales, CPA
Director, Interim CFO

- Broad leadership experience in the US and Latin America with Fortune 100 and early-stage start-up companies
- Senior executive/consulting roles with Citibank, Bank of America, Arthur Andersen, McDonald's, and Mazda
- University of Southern California; Licensed California CPA

Philippe Marchand, PhD
COO

- 20+ years experience in oncology diagnostics and biopharma industries
- Proven operations and technology track record as an executive
- Extensive experience in rare cell isolation and analysis technologies

Michael Dugan, MD
CMO and
Medical Director

- Board certified Pathologist
- Univ of AZ, Yale, UCLA
- Numerous publications, serves on CAP committees
- Leadership positions at Exact Sciences, Clinical Genomics, Quest, Genzyme and others

Darrell Taylor, JD
SVP, CLO & CCO

- 20+ years of extensive legal expertise focusing on healthcare transactional, regulatory, and compliance matters
- 15+ years on the provider side at LabCorp of America and other clinical and research laboratories
- Formerly with global law firm DLA Piper and in-house at Abbott Labs, AbbVie, and Sorrento Therapeutics
- The University of Texas Medical Branch and Notre Dame Law School

Michael Terry
SVP, Corporate Development

- 25+ years commercial leadership experience in molecular diagnostics and med-tech companies
- Former GE Healthcare executive, certified in Six Sigma
- Recent experience in liquid biopsy field; EVP commercial operations at both Sequenom and Trovagene

David Karlander
SVP, Commercial Operations

- 25+ years of industry experience including extensive oncology experience
- Record of success in building and managing major diagnostics brands
- Former executive sales and marketing positions at Exact Sciences and Novartis' Genoptix Medical Lab

GENOPTIX®
MEDICAL LABORATORY



BANK OF AMERICA



sequenom



Board of Visionaries & Scientific Influencers

Board of Directors

- **Samuel D. Riccitelli**
Chair, Interim President & CEO
- **Marsha A. Chandler, PhD**
Director, Chair of Nominating and Governance Committee
- **Bruce E. Gerhardt, CPA**
Director, Chair of Compensation Committee
- **Antonino Morales, CPA**
Director, Interim CFO
- **Ivor Royston, MD**
Director, Chair of Science and Technology Committee
- **Linda Rubinstein**
Director
- **M. Faye Wilson, CPA, MBA**
Lead Independent Director, Chair of Audit Committee

Lead Clinical Advisors

- **David Berz, MD, PhD**
Beverly Hills Cancer Center
Chief Medical Officer – Valkyrie Pharmaceuticals
Beverly Hills, California
- **Santosh Kesari, MD, PhD**
Chair, Dept. of Translational Neuro-oncology and
Neurotherapeutics, John Wayne Cancer Institute,
Santa Monica, California
- **Priya Kumthekar, MD**
Associate Professor of Neurology (Neuro Oncology)
and Medicine (Hematology and Oncology)
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL

Corporate Priorities

1

Position Biocept as leader in emerging category of neurological tumor diagnostics

2

Establish CNSide as standard of care for diagnosis, identifying potential treatments and monitoring for CNS involvement

3

Initiate FORESEE clinical validity & utility study leading to guideline inclusion – 1st patient enrolled in 3Q'22

4

Facilitate metastatic brain cancer therapy development by establishing revenue-generating biopharma company partnerships

5

Initiate company-sponsored investigator studies to support clinical validation and expanded use – 1st study initiated by 2022-year end

6

Develop additional strategic commercial and technology partnerships to accelerate neurological diagnostic offerings

7

Publish CNSide clinical study results in respected, peer-reviewed journals

8

Establish MoDx reimbursement commensurate with findings from published clinical studies

Investment Highlights

- Commercializing CNSide assay to test for cancer involvement in CNS; initial U.S. market opportunity of \$1.2B
- Expanding CNSide usage among neuro-oncologist KOLs
- Pursuing CNSide standard of care status to support broader adoption and higher reimbursement
- Targeting collaborations with biopharma partners using CNSide assay to support therapeutics clinical trials
- Serving the community and supporting our cash position with COVID-19 RT-PCR testing

Dedicated to improving outcomes for patients with advanced cancer.

